Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
Martin Thelen,Kerstin Wennhold,Jonas Lehmann,Maria Garcia-Marquez,Sebastian Klein,Elena Kochen,Philipp Lohneis,Axel Lechner,Svenja Wagener-Ryczek,Patrick Sven Plum,Oscar Velazquez Camacho,David Pfister,Fabian Dörr,Matthias Heldwein,Khosro Hekmat,Dirk Beutner,Jens Peter Klussmann,Fabinshy Thangarajah,Dominik Ratiu,Wolfram Malter,Sabine Merkelbach-Bruse,Christiane Josephine Bruns,Alexander Quaas,Michael von Bergwelt-Baildon,Hans A. Schlößer
DOI: https://doi.org/10.1038/s41698-021-00196-x
2021-06-16
npj Precision Oncology
Abstract:Abstract The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells as the most common feature, while other lymphocyte subsets and also expression of immune-regulatory molecules on tumor-infiltrating lymphocytes showed site-specific variation. Multiparametric analyses of these data identified similarities of renal and liver or lung with head and neck cancer. Co-expression of immune-inhibitory ligands on tumor cells was most frequent in colorectal, lung and ovarian cancer. Genes related to antigen presentation were frequently dysregulated in liver and lung cancer. Expression of co-inhibitory molecules on tumor-infiltrating T cells accumulated in advanced stages while T-cell abundance was related to enhanced expression of genes related to antigen presentation. Our results promote evaluation of cancer-specific or even personalized immunotherapeutic combinations to overcome primary or secondary resistance as major limitation of immune-checkpoint inhibition.
oncology